Agilent Technologies (NYSE:A) Downgraded by ValuEngine to Hold

ValuEngine cut shares of Agilent Technologies (NYSE:A) from a buy rating to a hold rating in a research note published on Friday, ValuEngine reports.

Other research analysts have also issued reports about the stock. Barclays reissued a hold rating on shares of Mettler-Toledo International in a research note on Wednesday, May 15th. Cowen increased their target price on shares of Agilent Technologies from $80.00 to $90.00 and gave the stock an outperform rating in a research note on Tuesday, March 26th. Bank of America reissued a buy rating on shares of Continental in a research note on Wednesday, May 15th. Wolfe Research initiated coverage on shares of Waters in a research note on Thursday, May 30th. They set an underperform rating on the stock. Finally, Piper Jaffray Companies set a $29.00 target price on shares of Bausch Health Companies and gave the stock a buy rating in a research note on Tuesday, June 11th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Agilent Technologies has an average rating of Buy and an average price target of $85.69.

Shares of NYSE A opened at $70.55 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.82 and a current ratio of 3.41. Agilent Technologies has a 52-week low of $61.01 and a 52-week high of $82.27. The company has a 50 day simple moving average of $71.49. The firm has a market cap of $22.64 billion, a PE ratio of 25.29, a P/E/G ratio of 2.00 and a beta of 1.41.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Tuesday, May 14th. The medical research company reported $0.71 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.72 by ($0.01). Agilent Technologies had a net margin of 22.25% and a return on equity of 19.71%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the company posted $0.65 earnings per share. The company’s revenue was up 2.7% compared to the same quarter last year. On average, analysts expect that Agilent Technologies will post 3.05 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd will be issued a dividend of $0.164 per share. The ex-dividend date is Monday, July 1st. This represents a $0.66 dividend on an annualized basis and a yield of 0.93%. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.66%.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Fruth Investment Management increased its stake in shares of Agilent Technologies by 0.8% in the second quarter. Fruth Investment Management now owns 44,539 shares of the medical research company’s stock worth $3,325,000 after purchasing an additional 338 shares in the last quarter. Xact Kapitalforvaltning AB increased its stake in shares of Agilent Technologies by 4.0% in the second quarter. Xact Kapitalforvaltning AB now owns 66,040 shares of the medical research company’s stock worth $4,931,000 after purchasing an additional 2,519 shares in the last quarter. Palmer Knight Co increased its stake in shares of Agilent Technologies by 3.7% in the second quarter. Palmer Knight Co now owns 58,165 shares of the medical research company’s stock worth $4,343,000 after purchasing an additional 2,067 shares in the last quarter. AMF Pensionsforsakring AB increased its stake in shares of Agilent Technologies by 190.3% in the second quarter. AMF Pensionsforsakring AB now owns 17,420 shares of the medical research company’s stock worth $1,301,000 after purchasing an additional 11,420 shares in the last quarter. Finally, LGT Capital Partners LTD. purchased a new position in shares of Agilent Technologies in the second quarter worth about $15,194,000.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: Insider Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.